Cellares

South San Francisco, CA
Platform Provider
CAR-T Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
60.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP

Quick Facts: Cellares

Signal Score
60.5/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
South San Francisco, CA
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Cellares

Industry 4.0 IDMO model. Cell Shuttle.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 61.0
Regulatory milestones (2 articles)
Sites: South San Francisco, CA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
Regulatory milestones (2 articles)
Sites: South San Francisco, CA
Recent Press20 articles
Regulatory milestones (2 articles)

Recent News 20 articles

general 2026-05-05
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply  MyChesCo
Source →
general 2026-05-01
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal - megaproject.com
Cellares, Cabaletta Bio sign 10-year CAR-T therapy commercial supply deal  megaproject.com
Source →
general 2026-04-29
Cellares to manufacture Cabaletta CAR-T under 10-year deal - NJBIZ
Cellares to manufacture Cabaletta CAR-T under 10-year deal  NJBIZ
Source →
general 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
Cabaletta Bio signs 10-year manufacturing deal with Cellares  Investing.com
Source →
general 2026-04-28
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel  Business Wire
Source →
general 2026-04-28
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel  The Manila Times
Source →
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Canada
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com Canada
Source →
general 2026-04-28
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel  BioSpace
Source →
general 2026-04-28
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy  Contract Pharma
Source →
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com UK
Source →
general 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com UK
Cabaletta Bio signs 10-year manufacturing deal with Cellares  Investing.com UK
Source →
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com
Source →
regulatory 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com  Investing.com India
Source →
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Australia
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com Australia
Source →
regulatory 2026-04-28
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com India
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com  Investing.com India
Source →
general 2026-04-28
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel  Investing.com UK
Source →
general 2026-04-15
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy - The National Law Review
Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy  The National Law Review
Source →
general 2026-04-14
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - Business Wire
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform  Business Wire
Source →
general 2026-04-14
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients - Genetic Engineering and Biotechnology News
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients  Genetic Engineering and Biotechnology News
Source →
general 2026-04-14
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today
Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform  National Today
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.8
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Rose BioSolutions
San Francisco, CA (GI Partners parent); operating HQ inherited from Charles River CDMO businesses
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy